The Therapeutic Effect of Coenzyme Q10 in HIV-Infected Patients
Phase 3
- Conditions
- Human immunodeficiency virus.Human immunodeficiency virus disease
- Registration Number
- IRCT201108027197N1
- Lead Sponsor
- Vice chancellor for research of Ahvaz Jundishapur University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 76
Inclusion Criteria
Inclusion criteria :
HIV-infected adults that HIV confirmed with 2 positive result of ELISA and western blot test and they are in treatment with ART
Exclusion criteria:
1- Lymphoma or other malignancies
2- Corticosteroids usage
3- Autoimmune Diseases
4- Advanced Pulmonary Tuberculosis
5- Pregnancy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CD4 level. Timepoint: Base line and 3 months after initiation of treatment. Method of measurement: flow cytometry method.
- Secondary Outcome Measures
Name Time Method ALT. Timepoint: Baseline and 3 months after initiation of treatment. Method of measurement: Device analysis.;AST. Timepoint: Baseline and 3 months after initiation of treatment. Method of measurement: Device analysis.;BUN. Timepoint: Baseline and 3 months after initiation of treatment. Method of measurement: Device analysis.;Cr. Timepoint: Baseline and 3 months after initiation of treatment. Method of measurement: Device analysis.;CBC. Timepoint: Baseline and 3 months after initiation of treatment. Method of measurement: Device analysis.